½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1266611

¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Áúº´ À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Tinea Pedis Treatment Market Size study & Forecast, by Disease Type, by Route of Administration, by Distribution Channel and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹«Á»Àº Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum°ú °°Àº ÇǺλç»ó±Õ¿¡ ÀÇÇÑ ¹ß °õÆÎÀÌ °¨¿°À¸·Î ¹ß°¡¶ô°ú ¼Õ¿¡µµ ÆÛÁú ¼ö ÀÖ½À´Ï´Ù. ¹ß°¡¶ô°ú ¼Õ¿¡ ÆÛÁú ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ °õÆÎÀÌ´Â µû¶æÇÏ°í ½ÀÇÑ È¯°æÀ» ¼±È£Çϸç, °¨¿°µÈ »ç¶÷°úÀÇ Á¢ÃËÀ» ÅëÇØ °¨¿°µË´Ï´Ù. ¿­´ë ¹× ¾Æ¿­´ë ±âÈÄ Áö¿ª¿¡¼­´Â ¹«Á»ÀÌ À¯ÇàÇÕ´Ï´Ù. ¼Õ¹ßÀÇ ¹ß°¡¶ô »çÀÌ ºÎÀ§¿¡¼­ ¹«Á»Àº ħÀ±, ¸í¹éÇÑ ±Õ¿­ ¹× ºñ´ÃÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹«Á»Àº °¨¿°·ÂÀÌ ¾àÇÒ ¶§´Â Ç×Áø±ÕÁ¦ ¿Ü¿ëÁ¦·Î Ä¡·áÇÒ ¼ö ÀÖÁö¸¸, ½ÉÇØÁö¸é Ç×Áø±ÕÁ¦ ³»º¹ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹ú·¹¿Í ¹ÚÅ׸®¾Æ¿¡ ÀÇÇÑ °õÆÎÀÌ °¨¿°ÀÇ À¯º´·ü Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡´Â ¹«Á» ¼¼°è ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, Áö±¸ ¿Â³­È­¿Í ±¹Á¦ ¿©Çà ¹× ¹«¿ª Áõ°¡·Î ÀÎÇØ °õÆÎÀÌ °¨¿°ÀÇ ¹ß»ýÀÌ ¼ö³â µ¿¾È ´«¿¡ ¶ç°Ô Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, GAFFI(Global Action for Fungal Infection)ÀÇ ÃßÁ¤¿¡ µû¸£¸é, 2022³â ÇöÀç ¼¼°èÀûÀ¸·Î 3¾ï ¸í ÀÌ»óÀÇ »ç¶÷µéÀÌ ½É°¢ÇÑ °õÆÎÀÌ °¨¿°À» ¾Î°í ÀÖÀ¸¸ç, 2,500¸¸ ¸í ÀÌ»óÀÌ »ç¸ÁÇÒ À§ÇèÀÌ ³ô´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¼¼°èÀºÇà ±×·ì¿¡ µû¸£¸é, 2020³â ¼¼°è ³ëÀÎ Àα¸´Â 7¾ï 2,700¸¸ ¸íÀ¸·Î ÇâÈÄ 30³â°£ 3¹è Áõ°¡ÇØ 2050³â¿¡´Â 15¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ¸é¿ª °áÇÌ È¯ÀÚ Áõ°¡¿Í ½ÅÈï °æÁ¦±¹ÀÇ ÇコÄÉ¾î »ê¾÷ÀÇ ¼ºÀåÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±×·¯³ª ¹«Á» Ä¡·áÀÇ ³ôÀº ºñ¿ë°ú ±î´Ù·Î¿î ÀǾàÇ° ½ÂÀÎ ÀýÂ÷´Â 2022-2029³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¹«Á» Ä¡·áÀÇ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ºê·£µå Á¦Ç°ÀÇ ¿ìÀ§¿Í ÀÌ Áö¿ªÀÇ ÁÖ¿ä ½ÃÀå ±â¾÷µéÀÇ ½ÅÁ¦Ç° °³¹ß Áõ°¡·Î ÀÎÇØ ¼öÀÍ Ãø¸é¿¡¼­ ½ÃÀåÀ» Áö¹èÇÏ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³ë·É Àα¸ ¹× ´ë»ó Àα¸ Áõ°¡, °õÆÎÀÌ °¨¿° Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â µ¿¾È ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆľÇÇÏ°í ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • ¼¼°è¡¤ºÎ¹®º° ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
    • ¹«Á» Ä¡·á ½ÃÀå, Áö¿ªº°, 2019-2029³â
    • ¹«Á» Ä¡·á ½ÃÀå, Áúȯ À¯Çüº°, 2019-2029³â
    • ¹«Á» Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2029³â
    • ¹«Á» Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2019-2029³â
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • Á¶»ç ´ë»ó ¹üÀ§
    • »ê¾÷ ÁøÈ­
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå ¿ªÇÐ

  • ¹«Á» Ä¡·á ½ÃÀåÀÇ ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è °ü°èÀÚÀÇ Àü¸Á
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦5Àå ¸®½ºÅ© Æò°¡ : COVID-19ÀÇ ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡°Ô ÁÖ´Â ÀüüÀûÀÎ ¿µÇâ¿¡ °üÇÑ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄÀÇ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : Áúȯ À¯Çüº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : Áúȯ À¯Çüº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå Áúȯ À¯Çüº° ÃßÁ¤¡¤¿¹Ãø(2019-2029³â)
  • ¹«Á» Ä¡·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Interdigital Tinea Pedis
    • 6.4.2. Plantar Tinea Pedis
    • 6.4.3. Vesicular Tinea Pedis

Á¦7Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°, ½ÇÀû-ÀáÀç ´É·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå Åõ¿© °æ·Îº° ÃßÁ¤¡¤¿¹Ãø(2019-2029³â)
  • ¹«Á» Ä¡·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °æ±¸
    • ±¹¼Ò

Á¦8Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : À¯Åë ä³Îº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå ÃßÁ¤¡¤¿¹Ãø(À¯Åë ä³Îº°) 2019-2029
  • ¹«Á» Ä¡·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • º´¿ø³» ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • E-Commerce

Á¦9Àå ¼¼°èÀÇ ¹«Á» Ä¡·á ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ¹«Á» Ä¡·á ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • Áúȯ À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
      • Åõ¿© °æ·Îº° ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
      • À¯Åë ä³Îº° ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
    • ij³ª´Ù
  • À¯·´ÀÇ ¹«Á» Ä¡·á ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹«Á» Ä¡·á ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¹«Á» Ä¡·á ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • ¼¼°è ±âŸ Áö¿ª

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Zimmer Biomet
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Smith & Nephew
    • Djo(Encore)
    • Zirkonzahn
    • Waldemar Link
    • Dragonbio
    • Stryker
    • Aesculap(B. Braun)
    • United Orthopedic Corporation
    • GlaxoSmithKline PLC

Á¦11Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ¹ë¸®µ¥À̼Ç
    • ÃâÆÇ
  • Á¶»ç Ư¡
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
LSH 23.05.23

Global Tinea Pedis Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Tinea pedis is a fungal infection of the feet caused by dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, which can spread to the toes and hands. These fungi prefer warm, moist environments and are spread by coming into contact with an infected person. In areas with tropical and subtropical climates, tinea pedis is more prevalent. In the interdigital regions of the hands and feet, tinea pedis can cause maceration, evident fissuring, and scaling. When tinea pedis is just weakly infected, it can be treated with topical antifungals, but severe infections need oral antifungal medications. The rising prevalence of fungal infections caused by worms and bacteria, as well as growing geriatric population is contributing towards the growth of the Global Tinea Pedis Market.

As per World Health Organization, the incidences of fungal infections have significantly increased over the years due to global warming and the increase in international travel and trade. For instance - as per Global Action for Fungal Infection (GAFFI) organization estimates- as of 2022, Globally over 300 million individuals are afflicted with a serious fungal infection and more than 25 million are at high risk of dying. Furthermore, the increasing number of geriatric individuals is another factor driving the market growth. According to the World Bank Group, the world's old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Also, rise in the number of immunocompromised patients and growing healthcare industry in developing economies would offer lucrative growth opportunities for the market over the projected period. However, high cost of Tinea Pedis Treatment and stringent drug approval process hinder the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Tinea Pedis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the increasing number of new product development from leading market players in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing incidences of fungal infections in the region.

Major market players included in this report are:

  • Zimmer Biomet
  • Smith & Nephew
  • Djo (Encore)
  • Zirkonzahn
  • Waldemar Link
  • Dragonbio
  • Stryker
  • Aesculap (B. Braun)
  • United Orthopedic Corporation
  • GlaxoSmithKline PLC

Recent Developments in the Market:

  • In March 2022, Blueberry Therapeutics Limited, a leading company offering topical medicines to treat dermatological conditions, announced the commencement of research and development activities for new formulations for onychomycosis (fungal nail infection), tinea pedis (athlete's foot) and atopic dermatitis (eczema).

Global Tinea Pedis Treatment Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Disease Type, Route of Administration, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Disease Type

  • Interdigital Tinea Pedis
  • Plantar Tinea Pedis
  • Vesicular Tinea Pedis

By Route of Administration

  • Oral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Tinea Pedis Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Tinea Pedis Treatment Market, by Disease Type, 2019-2029 (USD Billion)
    • 1.2.3. Tinea Pedis Treatment Market, by Route of Administration, 2019-2029 (USD Billion)
    • 1.2.4. Tinea Pedis Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Tinea Pedis Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Tinea Pedis Treatment Market Dynamics

  • 3.1. Tinea Pedis Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of infectious diseases caused by bacteria, viruses, and fungus
      • 3.1.1.2. Growing Geriatric Population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Tinea Pedis Treatment
      • 3.1.2.2. Stringent drug approval process
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rise in the number of immunocompromised patients
      • 3.1.3.2. Growing healthcare industry in developing economies

Chapter 4. Global Tinea Pedis Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Tinea Pedis Treatment Market, by Disease Type

  • 6.1. Market Snapshot
  • 6.2. Global Tinea Pedis Treatment Market by Disease Type, Performance - Potential Analysis
  • 6.3. Global Tinea Pedis Treatment Market Estimates & Forecasts by Disease Type 2019-2029 (USD Billion)
  • 6.4. Tinea Pedis Treatment Market, Sub Segment Analysis
    • 6.4.1. Interdigital Tinea Pedis
    • 6.4.2. Plantar Tinea Pedis
    • 6.4.3. Vesicular Tinea Pedis

Chapter 7. Global Tinea Pedis Treatment Market, by Route of Administration

  • 7.1. Market Snapshot
  • 7.2. Global Tinea Pedis Treatment Market by Route of Administration, Performance - Potential Analysis
  • 7.3. Global Tinea Pedis Treatment Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
  • 7.4. Tinea Pedis Treatment Market, Sub Segment Analysis
    • 7.4.1. Oral
    • 7.4.2. Topical

Chapter 8. Global Tinea Pedis Treatment Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Tinea Pedis Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Tinea Pedis Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 8.4. Tinea Pedis Treatment Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. E-Commerce

Chapter 9. Global Tinea Pedis Treatment Market, Regional Analysis

  • 9.1. Tinea Pedis Treatment Market, Regional Market Snapshot
  • 9.2. North America Tinea Pedis Treatment Market
    • 9.2.1. U.S. Tinea Pedis Treatment Market
      • 9.2.1.1. Disease Type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Tinea Pedis Treatment Market
  • 9.3. Europe Tinea Pedis Treatment Market Snapshot
    • 9.3.1. U.K. Tinea Pedis Treatment Market
    • 9.3.2. Germany Tinea Pedis Treatment Market
    • 9.3.3. France Tinea Pedis Treatment Market
    • 9.3.4. Spain Tinea Pedis Treatment Market
    • 9.3.5. Italy Tinea Pedis Treatment Market
    • 9.3.6. Rest of Europe Tinea Pedis Treatment Market
  • 9.4. Asia-Pacific Tinea Pedis Treatment Market Snapshot
    • 9.4.1. China Tinea Pedis Treatment Market
    • 9.4.2. India Tinea Pedis Treatment Market
    • 9.4.3. Japan Tinea Pedis Treatment Market
    • 9.4.4. Australia Tinea Pedis Treatment Market
    • 9.4.5. South Korea Tinea Pedis Treatment Market
    • 9.4.6. Rest of Asia Pacific Tinea Pedis Treatment Market
  • 9.5. Latin America Tinea Pedis Treatment Market Snapshot
    • 9.5.1. Brazil Tinea Pedis Treatment Market
    • 9.5.2. Mexico Tinea Pedis Treatment Market
    • 9.5.3. Rest of Latin America Tinea Pedis Treatment Market
  • 9.6. Rest of The World Tinea Pedis Treatment Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Zimmer Biomet
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Smith & Nephew
    • 10.2.3. Djo (Encore)
    • 10.2.4. Zirkonzahn
    • 10.2.5. Waldemar Link
    • 10.2.6. Dragonbio
    • 10.2.7. Stryker
    • 10.2.8. Aesculap (B. Braun)
    • 10.2.9. United Orthopedic Corporation
    • 10.2.10. GlaxoSmithKline PLC

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦